- Home
- GTBP vs OGEN Comparison
GTBP vs OGEN Comparison
Compare GTBP & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTBP
- OGEN
- Stock Information
- Founded
- GTBP 1965
- OGEN 1996
- Country
- GTBP United States
- OGEN United States
- Employees
- GTBP N/A
- OGEN N/A
- Industry
- GTBP Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GTBP Health Care
- OGEN Health Care
- Exchange
- GTBP Nasdaq
- OGEN Nasdaq
- Market Cap
- GTBP 5.5M
- OGEN 4.6M
- IPO Year
- GTBP N/A
- OGEN N/A
- Fundamental
- Price
- GTBP $2.23
- OGEN $0.20
- Analyst Decision
- GTBP Strong Buy
- OGEN
- Analyst Count
- GTBP 1
- OGEN 0
- Target Price
- GTBP $11.00
- OGEN N/A
- AVG Volume (30 Days)
- GTBP 17.4K
- OGEN 351.6K
- Earning Date
- GTBP 05-15-2025
- OGEN 05-09-2025
- Dividend Yield
- GTBP N/A
- OGEN N/A
- EPS Growth
- GTBP N/A
- OGEN N/A
- EPS
- GTBP N/A
- OGEN N/A
- Revenue
- GTBP N/A
- OGEN N/A
- Revenue This Year
- GTBP N/A
- OGEN N/A
- Revenue Next Year
- GTBP N/A
- OGEN N/A
- P/E Ratio
- GTBP N/A
- OGEN N/A
- Revenue Growth
- GTBP N/A
- OGEN N/A
- 52 Week Low
- GTBP $1.72
- OGEN $0.16
- 52 Week High
- GTBP $10.66
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- GTBP 46.01
- OGEN 52.52
- Support Level
- GTBP $2.30
- OGEN $0.18
- Resistance Level
- GTBP $2.37
- OGEN $0.22
- Average True Range (ATR)
- GTBP 0.15
- OGEN 0.02
- MACD
- GTBP -0.01
- OGEN 0.00
- Stochastic Oscillator
- GTBP 14.55
- OGEN 66.67
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.